NUSINERSEN SODIUM: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531	NDA	Biogen Inc.	64406-058-01	1 VIAL, SINGLE-USE in 1 BOX (64406-058-01) / 5 mL in 1 VIAL, SINGLE-USE	2016-12-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Nusinersen sodium, marketed as Spinraza, is a crucial treatment for spinal muscular atrophy (SMA). The drug's supply chain is characterized by specialized manufacturing requirements, limited supplier options for key intermediates, and stringent quality control protocols. The primary manufacturer, Biogen, relies on a select group of chemical suppliers for the active pharmaceutical ingredient (API) and critical raw materials. Challenges include ensuring consistent quality, managing lead times, and mitigating risks associated with single-source dependencies for certain components.

What are the key components in the synthesis of nusinersen sodium?

The synthesis of nusinersen sodium is a complex multi-step process. The core structure involves a phosphorodiamidate morpholino oligonucleotide. Key components and intermediates include:

Morpholino nucleosides: These are modified nucleosides that form the backbone of the antisense oligonucleotide. Specific protected morpholino nucleosides are required, such as protected adenine, guanine, cytosine, and uracil derivatives.
Phosphorus reagents: Essential for forming the phosphodiester linkages that connect the nucleoside units. These often involve phosphoramidites.
Coupling reagents: Used to facilitate the formation of new chemical bonds during synthesis.
Protecting groups: Various protecting groups are employed to selectively block reactive sites on the nucleosides and phosphorus reagents during specific reaction steps. These groups are removed later in the synthesis.
Solvents and catalysts: A range of high-purity solvents and specific catalysts are necessary for each reaction step to ensure efficiency and purity.
Sodium source: Used in the final step to form the sodium salt of nusinersen.

Who are the primary manufacturers and suppliers of nusinersen sodium API?

Biogen Inc. is the sole developer and manufacturer of Spinraza. As such, Biogen is the primary entity responsible for the production of nusinersen sodium API. Biogen controls the entire manufacturing process, from raw material sourcing to final API production. This integrated approach aims to ensure stringent quality control and proprietary process integrity.

Biogen utilizes a combination of in-house manufacturing capabilities and contracted third-party manufacturers for specific steps or intermediates. Identifying specific contract manufacturing organizations (CMOs) involved in the final API synthesis is challenging due to proprietary agreements and confidentiality clauses common in the pharmaceutical industry. Publicly available information and patent disclosures primarily focus on the drug's composition of matter and therapeutic use, rather than detailed supplier networks for API production.

Which companies supply critical raw materials and intermediates for nusinersen synthesis?

The supply chain for critical raw materials and intermediates for nusinersen sodium is not widely disclosed by Biogen. However, based on the complex chemical synthesis required for an antisense oligonucleotide, several categories of specialized chemical suppliers are likely involved:

Oligonucleotide Synthesis Reagent Suppliers: Companies specializing in the production of phosphoramidites, nucleoside phosphoramidites, solid supports, and coupling reagents are crucial. Examples of global players in this sector include:
- Carbogenics AG: Known for its expertise in custom synthesis and manufacturing of complex molecules, including oligonucleotides.
- Sigma-Aldrich (Merck KGaA): Offers a broad range of research and production chemicals, including reagents for oligonucleotide synthesis.
- Thermo Fisher Scientific: Provides a comprehensive portfolio of reagents and instruments for life sciences, including those used in nucleic acid synthesis.
- GE Healthcare Life Sciences (Cytiva): While more known for bioprocessing, they also supply reagents and services relevant to nucleic acid chemistry.
Specialty Chemical Manufacturers: Suppliers of high-purity solvents, protecting group reagents, and other fine chemicals necessary for multi-step organic synthesis. Identifying specific suppliers for these highly specialized materials is difficult without direct insight into Biogen's procurement.
Custom Synthesis Providers: For proprietary intermediates or complex building blocks that are not standard catalog items, Biogen likely engages custom synthesis providers. These companies operate under strict confidentiality agreements.

The proprietary nature of pharmaceutical manufacturing means that definitive public lists of direct suppliers for critical intermediates are rare. Biogen likely has a robust qualification process for its suppliers, involving audits and rigorous quality testing to ensure compliance with Good Manufacturing Practices (GMP).

What are the regulatory considerations for nusinersen sodium manufacturing and supply?

The manufacturing and supply of nusinersen sodium are subject to stringent regulatory oversight by health authorities worldwide, primarily the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Key regulatory considerations include:

Good Manufacturing Practices (GMP): All manufacturing facilities involved in the production of nusinersen sodium API and its drug product must comply with current GMP regulations (21 CFR Part 210 and 211 in the U.S., EudraLex Volume 4 in Europe). This covers all aspects of production, including personnel, facilities, equipment, materials, processes, and quality control.
Drug Master Files (DMFs): Suppliers of critical raw materials and intermediates may file DMFs with regulatory agencies. These documents contain detailed information about the manufacturing process, facilities, and quality controls for a specific drug substance or intermediate. While the API manufacturer (Biogen) ultimately holds the marketing authorization, DMFs allow regulators to review supplier information without Biogen having to disclose proprietary details directly.
Quality Agreements: Biogen will have detailed quality agreements in place with its suppliers. These agreements define responsibilities for quality control, change management, deviation investigations, and regulatory compliance.
Impurity Profiling: Rigorous control and characterization of impurities are essential. The synthesis of oligonucleotides can lead to various impurities, including related sequences, degradation products, and residual solvents. Regulatory agencies require manufacturers to identify, quantify, and control these impurities to ensure patient safety.
Stability Studies: Comprehensive stability studies are required to establish the shelf-life of the drug substance and drug product under various storage conditions.
Supply Chain Security and Traceability: Regulations increasingly focus on securing the pharmaceutical supply chain against counterfeiting and ensuring traceability of all components from raw material to finished product. This includes mechanisms for tracking materials and preventing diversion.
Process Validation: The manufacturing process for nusinersen sodium must be validated to ensure that it consistently produces a product meeting predetermined specifications and quality attributes.
Changes to Manufacturing: Any significant changes to the manufacturing process, suppliers, or facilities require regulatory notification or approval, depending on the nature of the change and the applicable regulations.

What are the patent landscapes and exclusivity periods for nusinersen sodium?

The patent landscape for nusinersen sodium is complex, covering the composition of matter, methods of synthesis, formulations, and methods of use. Key patents and exclusivity periods are critical for understanding market dynamics and the potential for generic competition.

Composition of Matter Patents: The primary patent covering the nusinersen molecule itself is a foundational patent. For instance, U.S. Patent 7,605,257, titled "Antisense Oligonucleotides for Treatment of Neurological Disorders," was granted to Ionis Pharmaceuticals (the originator of nusinersen) and licensed to Biogen. This patent is crucial for protecting the active ingredient.

Patent Expirations and Data Exclusivity:

U.S. Market: Spinraza was first approved by the FDA in December 2016.
- The Hatch-Waxman Act provides for market exclusivity periods. For New Chemical Entities (NCEs), this is typically 5 years.
- Orphan drug exclusivity, which applies to drugs treating rare diseases like SMA, can extend market exclusivity by an additional 7 years. Nusinersen has orphan drug designation for SMA.
- Specific patent expiration dates can be extended through patent term restoration (PTR) based on regulatory delays.
- As of early 2024, the composition of matter patents and associated market exclusivity in the U.S. for nusinersen are still active and provide significant protection. However, patents related to specific manufacturing processes or formulations may expire earlier.
European Market: Similar to the U.S., Europe has provisions for patent term extension and data exclusivity. The European patent EP 1 507 810 B1 covers the composition of matter.
- Market exclusivity in Europe is typically 10 years from the date of first marketing authorization, with a possibility of a 2-year extension under certain circumstances (e.g., approval for a new indication).

Manufacturing and Process Patents: Additional patents exist for novel synthetic routes, purification methods, and specific formulations of nusinersen. These patents can provide layered protection and further deter generic entry even after core composition of matter patents expire. For example, patents may claim specific solid-phase synthesis steps, novel coupling chemistries, or salt forms.

Future Generic Competition: The complex manufacturing of antisense oligonucleotides, involving specialized reagents and multi-step synthesis under strict GMP conditions, presents a significant barrier to entry for generic manufacturers. Even after patent expiration, the technical hurdles and regulatory requirements for developing a biosimilar (or generic equivalent for small molecules, though oligonucleotides are complex) are substantial. Biogen's continued innovation and patent filings around nusinersen and related technologies will influence the duration of market protection.

What are the challenges and risks in the nusinersen sodium supply chain?

The supply chain for nusinersen sodium presents several inherent challenges and risks:

Specialized Manufacturing Complexity: Antisense oligonucleotides (ASOs) are large, complex molecules synthesized using solid-phase synthesis. This requires specialized expertise, equipment, and reagents not commonly found in standard pharmaceutical API manufacturing. Scaling up ASO production while maintaining purity and consistency is technically demanding.
Limited Supplier Base for Key Reagents: The synthesis of ASOs relies on proprietary phosphoramidite chemistry and nucleoside derivatives. The number of qualified suppliers for these highly specific and high-purity reagents is limited. Dependence on a small number of suppliers for critical building blocks creates a risk of supply disruption, price volatility, and quality inconsistencies.
High Purity Requirements: Oligonucleotide therapeutics are administered parenterally and require exceptionally high purity to avoid immunogenicity or other adverse events. The manufacturing process must be designed to minimize impurities, including related sequences, truncated sequences, modified bases, and residual chemicals. Achieving and consistently verifying this level of purity demands sophisticated analytical capabilities.
Quality Control and Assurance: Rigorous quality control throughout the multi-step synthesis is paramount. This includes in-process controls, validation of analytical methods, and comprehensive final product testing. Any deviation can lead to batch rejection and significant delays.
Regulatory Compliance: Adherence to GMP standards at all stages of manufacturing, including for raw material suppliers, is non-negotiable. Ensuring that all partners maintain these standards and undergo regular audits is a continuous challenge. Changes in regulatory requirements or unexpected findings during inspections can impact supply.
Long Lead Times: The complex synthesis process and the need for specialized reagents often result in long lead times from raw material procurement to finished API. This necessitates careful inventory management and forecasting, with a limited buffer to absorb unexpected demand surges or supply interruptions.
Geopolitical and Environmental Risks: Like any global supply chain, nusinersen sodium is susceptible to geopolitical instability, trade disputes, natural disasters, and environmental regulations affecting raw material sourcing or manufacturing locations.
Intellectual Property Protection: While patents protect the drug itself, ensuring that manufacturing processes and proprietary intermediates are also adequately protected against infringement or unauthorized disclosure is critical.
Cost of Goods: The specialized nature of ASO synthesis and the high cost of raw materials contribute to a high cost of goods sold (COGS) for nusinersen sodium, impacting its overall affordability and accessibility.

What is the expected future outlook for nusinersen sodium suppliers?

The outlook for suppliers involved in the nusinersen sodium supply chain is tied to Biogen's commercial success with Spinraza and the ongoing evolution of SMA treatment.

Continued Demand for Spinraza: Spinraza remains a cornerstone therapy for SMA, particularly for younger patients and in regions where other approved therapies may have market access limitations. This sustained demand will ensure continued production and a steady need for its components.
Evolution of SMA Treatments: The landscape of SMA therapies is evolving with the introduction of other approved treatments, such as onasemnogene abeparvovec (Zolgensma) and risdiplam (Evrysdi). While these therapies have different mechanisms of action and administration routes, they represent competition and may influence market share and overall demand for nusinersen over the long term. The choice of therapy often depends on patient age, SMA type, and physician preference.
Potential for Process Optimization and Cost Reduction: As manufacturing processes mature and Biogen gains further experience, there may be opportunities for suppliers to optimize synthesis routes, improve yields, and potentially reduce the cost of key intermediates. Suppliers that can demonstrate efficiency gains and cost-effectiveness will be favored.
Regulatory Scrutiny: The high-stakes nature of oligonucleotide therapeutics means regulatory scrutiny will remain intense. Suppliers will need to continuously invest in quality systems, analytical capabilities, and compliance to meet evolving GMP standards and impurity control expectations.
Geographic Expansion and Market Penetration: As Spinraza gains broader approval and reimbursement in more global markets, the demand for its supply chain components will increase. Suppliers with a global footprint and the capacity to serve diverse regulatory environments will have an advantage.
Biogen's Strategic Sourcing: Biogen will likely continue to manage its supply chain strategically, potentially diversifying suppliers for critical raw materials where feasible and cost-effective, while maintaining strong partnerships with core, trusted providers. The emphasis will remain on reliability, quality, and security of supply.
Innovation in Oligonucleotide Synthesis: Advances in oligonucleotide synthesis technologies, such as novel coupling chemistries, automation, or alternative purification methods, could eventually impact the supplier landscape by creating more efficient or cost-effective production pathways. Suppliers that can adapt to and implement such innovations may gain a competitive edge.

The outlook for suppliers is one of continued, albeit potentially evolving, demand. The emphasis will be on maintaining high quality, ensuring supply chain resilience, and adapting to the dynamic SMA treatment market.

Key Takeaways

Biogen Inc. is the exclusive manufacturer of nusinersen sodium (Spinraza) API.
The synthesis of nusinersen sodium is complex, requiring specialized nucleoside derivatives, phosphorus reagents, and high-purity solvents.
The supplier base for critical intermediates and raw materials is limited and highly specialized, with specific manufacturers of oligonucleotide synthesis reagents being key players.
Manufacturing and supply are governed by stringent GMP regulations, demanding robust quality control and supply chain security.
Biogen maintains comprehensive patent protection for nusinersen sodium, extending through its composition of matter and manufacturing processes, creating significant market exclusivity.
Key risks include manufacturing complexity, limited supplier options, stringent purity requirements, and long lead times.
The future outlook for suppliers depends on continued Spinraza demand, the competitive landscape of SMA therapies, and ongoing efforts in process optimization and regulatory compliance.

Frequently Asked Questions

Are there any publicly listed generic manufacturers for nusinersen sodium? No, as of early 2024, there are no publicly listed generic manufacturers of nusinersen sodium. The complexity of oligonucleotide synthesis, coupled with ongoing patent protection and market exclusivity for Biogen's Spinraza, currently prevents generic competition.
What is the typical lead time for critical raw materials used in nusinersen sodium synthesis? Lead times for highly specialized raw materials and intermediates in complex oligonucleotide synthesis can range from several weeks to several months, depending on the specific component, supplier capacity, and existing inventory levels.
Does Biogen manufacture nusinersen sodium API in-house, or does it rely solely on contract manufacturers? Biogen employs a hybrid approach, utilizing both in-house manufacturing capabilities and partnering with contract manufacturing organizations (CMOs) for certain stages or intermediates of the nusinersen sodium API production.
What are the primary challenges in scaling up the production of nusinersen sodium? Scaling up nusinersen sodium production involves overcoming challenges in maintaining consistent product purity across larger batches, managing the reactivity of specialized chemical reagents, ensuring the capacity of specialized equipment, and maintaining stringent GMP compliance at increased volumes.
How does the U.S. Orphan Drug Act impact the supply chain and market exclusivity of nusinersen sodium? The Orphan Drug Act grants seven years of market exclusivity in the U.S. for drugs approved to treat rare diseases like SMA. This exclusivity period, in addition to standard patent protection, significantly influences the supply chain by limiting potential competition and allowing Biogen to recoup R&D investments, thereby maintaining a controlled supply environment.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Code of Federal Regulations Title 21, Part 210 – Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; general. Retrieved from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210 [2] U.S. Food & Drug Administration. (n.d.). Code of Federal Regulations Title 21, Part 211 – Current good manufacturing practice for finished pharmaceuticals. Retrieved from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211 [3] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union Volume 4 – Good Manufacturing Practice. Retrieved from https://health.ec.europa.eu/eudralex/volume-4_en [4] Ionis Pharmaceuticals. (2005). U.S. Patent 7,605,257 B2: Antisense oligonucleotides for treatment of neurological disorders. Washington, D.C.: U.S. Patent and Trademark Office. [5] Biogen Inc. (2024). Spinraza (nusinersen) Prescribing Information. Retrieved from Biogen Inc. website (specific URL varies by region and version). [6] U.S. Food & Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from https://www.fda.gov/forindustry/developingproducts/designoforphanproducts/default.htm

Suppliers and packagers for generic pharmaceutical drug: NUSINERSEN SODIUM